The potential of enzyme inhibition of a drug is frequently quantified in terms of IC 50 values. Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanismbased inhibitors (MBIs). IC 50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compounds with respect to their inhibitory potential. As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition constant (K I ) and the rate of enzyme inactivation (k inact ) rather than on IC 50 values. In this article, the authors derive a novel relation between potentially timedependent IC 50 values and K I , k inact parameters for different types of inhibition. This allows for direct estimation of K I and k inact values from timedependent IC 50 values, even without the need of additional preincuba tion experiments. The application of this approach is illustrated using a fluorimetric assay to access the drugdrug interaction potential associated with new chemical entities. The approach can easily be implemented using standard software tools (e.g., XLfit) and may also be suitable for applications where mechanismbased inhibition is a desired mode of action (e.g., at particular pharmacological drug targets). (Journal of Biomolecular
INTRODUCTION

C
haracterizing the potential of irreversible inactivation of an enzyme by a drug is useful-for example, when aiming at avoiding undesirable inhibition of metabolizing enzymes in the body (e.g., cytochrome P450 enzyme inhibition) or when aiming at efficiently inhibiting target enzymes (e.g., in cancer therapy). The potential of enzyme inhibition is frequently quantified in terms of IC 50 values, characterizing the degree to which the enzyme activity is inhibited, which are then used, for example, for ranking of new chemical entities in terms of their inhibitory potency.
Inhibition of cytochrome P450 enzymes is a principle mech anism for drugdrug interactions, which may cause severe complications in the clinics. 1 It is the underlying mechanism of some of the most notable drugdrug interactions of great est magnitude 2 -for example, paroxetine and CYP2D6, 3 clarithromycin and CYP3A, 4 and furanocoumarins and CYP3A. 5 To access the drugdrug interaction risks associ ated with new chemical entities (NCEs), in vitro studiesparticularly those using liver microsomes, hepatocytes, or recombinant CYPs-are being applied. 2, 6, 7 For a thorough dis cussion of the different approaches, see Bachmann, 7 Tucker et al., 8 and Zlokarnik et al. 9 One of the assays being employed is a microplate assay that uses cDNAexpressed human hepatic CYPs and fluorimetric substrates. 10 This assay allows a quick estimation of IC 50 values, which then can be used to rank com pounds according to their drugdrug interaction (DDI) poten tial. 11, 12 However, to predict the risk of a particular NCE for drugdrug interactions in the clinics, assays based on liver microsomes and drug substrates are much preferred-especially in the case of CYP 3A4, for which multiple binding sites have been described. 13 Mechanismbased inhibition can also be a desirable propertyfor example, when targeting enzymes in cancer therapy, 14 inhibiting prostatic acid phosphatases, 15 or zinc proteases. 16 The existing types of enzyme inhibition can be roughly divided into reversible and irreversible inhibition. Although much research has been conducted to understand reversible interactions, much less is known for irreversible or mechanism based inhibition. 2, 17, 18 Although simple and fast approaches based on the fluorimetric assay to identify mechanismbased inhibitors have been described in the literature, 19, 20 the determi nation of the kinetic parameters of inactivation has been left to more complex study designs employing different preincubation schemes. 21 In the case of reversible inhibition, conversions from IC 50 into the K I value are usually performed using the Cheng Prusoff equations. 19 For mechanismbased inhibition assays, in addition to the K I value, a second parameter, k inact , accounting for the irreversible inhibition has to be taken into account. This parameter is related to the timedependent decrease of IC 50 val ues for irreversible inhibition. 22 In this situation, the Cheng Prusoff equation results in erroneous predictions.
The objective of this article is to estimate the kinetic param eters K I and k inact directly from timedependent IC 50 measure ments without the need to perform additional preincubation experiments. To this end, we develop a general relation between IC 50 , K I , and k inact for mechanismbased inhibitors. It is based on a mathematical model of the experimental setup for the determination of the IC 50 . The assumptions, under which the general relation is valid, reflect the typical experimental condi tions of the in vitro assays. We illustrate this new approach using a fluorimetric assay where timedependent IC 50 values can easily be obtained by continuously measuring the plate in the fluorescence reader. Results are given for CYP450 isoen zymes 1A2 and 3A4 (i.e., enzymes with welldefined and complex binding characteristics, respectively). Estimated val ues for K I and k inact are generally in good agreement with exp erimental data from the literature.
MATERIAL AND METHODS
Materials
Baculovirus/insect cellexpressed human CYP1A2 and CYP3A4 microsomes (Supersomes), 3Cyano7Ethoxycoumarin (CEC), 7Benzyloxytrifluoromethylcoumarin (BFC), cofac tors, glucose6phosphate dehydrogenase, and potassium phos phate buffer were obtained from GENTEST/BD Biosciences (Woburn, MA). Test chemicals and their suppliers were as fol lows: raloxifene and ethinylestradiol were synthesized in the laboratories of Bayer Schering Pharma AG (Berlin, Germany). All other test compounds were purchased from SIGMA Aldrich (Munich, Germany).
Fluorimetric enzyme inhibition assay. Incubations were conducted in black 96well microplates (Greiner BioOne GmbH, Frickenhausen, Germany) based on the method described by GENTEST with slight modifications as described in the summary below. All incubations were performed in either 50 mM (CYP 1A2) or 200 mM (CYP 3A4) potassium phosphate buffer at pH 7.4 containing 8.1 µM NADP+, 0.41 mM MgCl 2 , 0.4 mM glucose6phosphate, and 0.2 IU/mL glucose 6phosphate dehydrogenase. Final concentrations of cyto chrome P450 enzymes and substrates were 2.5 nM CYP1A2, 5 nM CYP3A4, 5 µM CEC, and 50 µM BFC. All test com pounds were dissolved in acetonitrile and serially diluted (1:3) to 6 final concentrations ranging from 0.041 to 10 µM, keeping the final concentration of acetonitrile to 2% in all incubations. The plate with buffer, test compounds, and cofactors was pre warmed at 37°C, and the reaction was started by adding pre warmed (37°C) enzyme/substrate mixture. Fluorescence in each well was measured using a PerkinElmer Victor3 multi lable counter with temperature control set to 37°C. Instead of using endpoint measurements, CYP activity was determined at intervals of 2 min up to 30 min after start of reaction using an excitation/emission wavelength of 410/460 nm and 410/530 nm for CYP1A2 and CYP3A4, respectively. Usually, measure ments at very early time points are more difficult to obtain (and therefore often more error prone) due to the experimental setup. Because early measurements are not necessarily required for our proposed approach, measurements were taken starting from 5 min. For analysis fluorescence, data were exported to Excel, and IC 50 s at various time points were determined by fit ting the experimental data to a sigmoidal doseresponse model using XLfit (IDBS, Guildford, UK).
Models of enzyme inhibition
Experimentally, the inhibitory potential of an enzyme inhib itor is determined by measuring the decrease in metabolite formation by the enzyme in the presence of the inhibitormeasured using fluorimetric or liquid chromatography/mass spectrometry (LC/MC) assays.
The IC 50 value is typically defined as concentration of the inhibitor, at which the velocity of product formation is half the velocity without inhibitor. 19 For reversible inhibition, this is iden tical to the inhibitor concentration that decreases the metabolite concentration by 50%.
In the sequel, we present a theoretical approach that allows for determining the IC 50 in a way that exactly matches the experimental setup of the in vitro assay and defines the IC 50 in terms of the modeltheoretical analog of the fluorescent prod uct concentration. As a special case, we regain the wellknown ChengPrusoff equations, if we impose additional assumptions. These additional assumptions are typically satisfied for revers ible inhibition; however, they are clearly violated for the impor tant class of mechanismbased inhibitors.
In the following, we have chosen the 2 examples of com petitive inhibition and mechanismbased inhibition to derive a mathematical description of timedependent CYP inhibition. This allows for illustrating the common parts as well as the differences between our approach and the ChengPrusoff approach.
Product formation without inhibition. In the absence of any inhibitor, the product formation by a catalytic enzyme reaction typically comprises the following reaction steps:
The velocity of product formation is approximated by Michaelis Menten kinetics:
where V max = k catS ⋅ E cat denotes the maximal velocity of product formation defined in terms of the functional catalytic enzyme concentration E cat (here identical to the total enzyme concen tration), and K M denotes the substrate concentration, at which
Competitive inhibition. In the case of competitive inhibition, the inhibitor may form a complex with the free enzyme and thus decrease the rate at which the product is catalyzed. This is shown in the following reaction scheme:
The resulting velocity of product formation is then given by
where in addition to equation (2), the parameter K i = k -1 /k 1 denotes the dissociation constant of the inhibitorenzyme complex. We remark that for the above 2 models, the maximal velocity V max does not change over time because the underlying functional catalytic enzyme concentration is constant in time. This condi tion, however, is violated for the following type of inhibition.
Mechanism-based inhibition. This form of inhibition involves, in addition to the competitive inhibition, a reaction that irreversibly transforms the inhibitorenzyme complex into an "inactive" form, denoted by E:I * . The corresponding reac tion scheme is given by
where k inact describes the rate at which the inhibitorenzyme complex is irreversibly transformed into E:I * . The resulting equation for product formation is given by
where, due to the irreversible formation of E:I * , the functional catalytic enzyme concentration E cat (t) does decrease in time, resulting in a timedependent maximal velocity V max (t) = k cat . E cat (t). The maximal rate of inactivation is defined by the prod uct of k inact and the active enzyme concentration. The parameter K I is the inhibitor concentration that results in half the maximal rate. 4 A detailed description of the relation between K I and K i can be found in Mayhew et al. 4 The resulting timedependent decrease in functional catalytic enzyme requires establishing an additional evolution equation for E cat (t). To do so, we note that E tot = E cat + E:I * (t), where E tot denotes the total enzyme concentration in the system (that is assumed to be constant). Under steadystate conditions, the concentration of the enzymeinhibitor complex E:I(t) over time satisfies
from which we may derive the required equation: because E cat (t) =
which, combined with equation (7), results in
with initial condition E cat (0) = E tot and
To highlight the dependence of V max (t) on E cat in equation (6), we rewrite (6) as
Control and the definition of IC 50 . In many experimental approaches to determine IC 50 values, the increase in fluorescent product concentration is measured. Unlike many other theoreti cal approaches, our definition of the IC 50 directly builds on the fluorescent product concentration P(t) at time t. Let us define the control, a function of time t and inhibitor concentration I, as
P 0 (t) where P I (t) and P 0 (t) denote the concentration of product at time t in the presence of an inhibitor (at concentration I),
respectively, in the absence of any inhibitor. Based on the con trol, the IC 50 value is then defined as the inhibitor concentration at which the product concentration is half the concentration of the system without inhibitor, hence
This characterization is used to determine the relation between IC 50 , K I , and k inact . The IC 50 may depend on time, as is the case for mechanismbased inhibition. We note that the general solu tion to equations (2) and (4) is given by
with possibly timevarying velocities of product formation V I (t) and V 0 (t) in the presence and absence of the inhibitor, respectively. Under the addition assumptions that V 0 (t) and V I (t) are constant in time, and P 0 (0) = P I (0) = 0, equation (11) simplifies to
which is the starting point for the derivation of the well known ChengPrusoff relation between IC 50 and K I . These additional assumptions (V 0 (t) and V I (t) are constant in time and P 0 (0) = P I (0) = 0) are satisfied for reversible inhibitors (see Cheng and Prusoff 19 for other types of reversible inhibi tors), thereby including competitive inhibitors; however, they are not satisfied for mechanismbased inhibitors, as can be seen from equation (6) . This clearly shows that the ChengPrusoff approach must necessarily fail when aiming at mechanism based inhibition.
Cheng-Prusoff equation for competitive inhibition
Usually, the in vitro assay is set up in such a way that (A1) the amount of substrate does not change significantly during the performance of the assay (i.e., realized by choosing S >> E tot ), (A2) the amount of inhibitor does not change significantly in time, and (A3) the amount of catalytically active enzyme is constant in time. Under these assumptions, the resulting prod uct formation velocities in equations (2) and (1) are constant in time. Hence, assuming zero initial product concentration-that is, P 0 (0) = P I (0) = 0 (which is realized by subtracting back ground fluorescence)-we obtain
Finally, the IC 50 is determined by
which yields the wellknown ChengPrusoff equation for com petitive inhibition 19 :
Central relation between time-dependent IC 50 (t) values and the parameters K I and k inact
For mechanismbased inhibition, we assume that (A1) the amount of substrate does not change significantly during the performance of the assay, and (A2) the amount of inhibitor does not change significantly in time. We do not assume that the amount of catalytically active enzyme is constant in time.
Under these assumptions, we may explicitly solve for the fate of the catalytically active enzyme E cat in equation (8) because under these 2 assumptions, η I in (9) is constant in time:
Inserting E cat (t) into equation (10) results in
Solving (19) with P I (0) = 0 yields
In order to determine the IC 50 (t), we compute
with η IC 50 defined by (9) with I = IC 50 . Exploiting equation (12), we obtain
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This finally yields the central relation between timedependent IC 50 (t) values and the parameters K I and k inact .
The above equation illustrates that there is a specific curve of IC 50 values over time for every combination of K I and k inact (see Fig. 1 ). In a typical experimental setup, the parameters S, K M , and I, as well as a series of measured timedependent IC 50 values IC 50 (1), . . ., IC 50 (n) at different points in time t 1 , . . ., t n , are known. The task is then to determine K I and k inact , which can done by a least squares fit using equation (23) ) and as experimental data to fit the prediction of the model in equation (23) . As is well known, the precision of the estimated parameters typically increases with the number of experimental data points (IC 50 values) available. Therefore, using the proposed fluorimetric assay, the precision of K I and k inact estimation can be increased by increasing the frequency of fluorescence readouts. Figure 2 shows the complete process of determination of K I and k inact . A step bystep tutorial for realization in XLfit can be found online in the Supplement to this article at http://jbx.sagepub.com/ supplemental.
Solving equation (23) for K I , we nicely see the analogy to the original ChengPrusoff equation:
where the factor C depends on k inact , time, and η IC 50 :
Hence the central relation (23) can be interpreted as a corrected ChengPrusoff equation accounting for the timedependent loss of the functional catalytic enzyme. In the limit of vanishing k inact , we obtain C = 1 using l'Hopital's rule, which is consistent with equation (17) . In previous attempts, this factor has never been accounted for correctly (e.g., Maurer et al. 23 ).
RESULTS
The derived central relation (23) between K I , k inact , and the IC 50 values was validated in silico by generating concentration time profiles of the resulting product over 30 min using equa tion (19) (see Fig. 3, left) . Based on these data, theoretical IC 50 values were calculated at each minute based on equation (12) and used to validate relation (23) . In addition, we show the prediction based on the relation (B3) derived in Maurer et al. 23 As shown in Figure 3 (right) , the herein derived relation is in excellent agreement with the theoretical IC 50 values. In con trast, the relationship derived by Maurer et al. differs substan tially from the IC 50 values; in particular, it predicts negative IC 50 values.
The performance of the proposed approach was further evaluated based on fluorimetric assay data of 7 wellknown mechanismbased inhibitors (MBIs) for CYP450 isoforms 1A2 and 3A4. All MBIs showed the timedependent decrease in IC 50 values (see Fig. 4) . Clearly, the model predictions nicely describe the decrease of IC 50 values due to mechanismbased inhibition for all 6 inhibitors (see Fig. 5 ).
To access the accuracy of the estimated parameters of inhi bition, we provide a comparison to literature values that were obtained in human liver microsomes by use of the KitzWilson or nonlinear regression method. Based on the known parame ters S and K M , the inhibition parameters K I and k inact have been estimated by fitting model (23) to the timedependent IC 50 data. In Table 1 , the estimated values of K I and k inact (based on single fluorimetric assay experiments) are compared to values of K I and k inact estimated by classical data analysis methods (based on a series of preincubation experiments). As can be inferred from Table 1 , generally there is a good agreement between our esti mates and K I and k inact values based on classical data analysis methods. Calculated k inact values were within a maximal 2.5 fold error range of a literature value. K I values were also within a 2.5fold error range, except for ethinylestradiol and raloxifene.
Repeated experiments for verapamil, furafylline, and ethi nylestradiol with different sampling protocols were used to access the impact of experimental variability. Model predic tions are in good agreement with experimental IC 50 values even for small numbers of sampling points (Fig. 5) . The resulting estimates of K I and k inact for different numbers of sampling points can be found in Table 1 . 
DISCUSSION
Irreversible inactivation of enzymes by an inhibitor can be undesirable when drugmetabolizing enzymes are inhibited (e.g., cytochrome P450 enzymes) or beneficial when drug target enzymes are efficiently inhibited. In both cases, knowledge of the parameters of inhibition K I and k inact is useful to characterize the inhibitory potential. In this article, we derive a novel rela tion to directly estimate these 2 parameters from timedepend ent IC 50 values without the need of a series of measurements with increasing preincubation time. The proposed approach is generally applicable to experimental assays that provide a series of timedependent IC 50 values.
The theoretical derivation is tightly coupled to the experimen tal conduct of the assay-that is, the derivation is based only on assumptions, under which the in vitro experiment is typically performed. Under these assumptions, equation (23) provides a mathematically founded relation between the time dependence of IC 50 values and the parameters of inhibition K I and k inact . To the best of our knowledge, it is the first time that this key relation has been reported. Previous attempts were based on relating the IC 50 value directly to reaction velocities. 23 During the perform ance of the assays, however, product concentrations rather than reaction velocities are measured. Equation (14) states that con sidering concentrations or reaction velocities is equivalent for reversible inhibition. However, this is not the case for mechanism based inhibition. The difference between the 2 approaches is apparent from quality of predictions shown in Figure 3 . By definition, the velocity of product formation decreases over time in the presence of irreversible inhibitors. Consequently, compar ing reaction velocities at a particular time is only a snapshot of the inhibition process at that time. However, it does not take into account the gradual inactivation process and its accumulated effect up to that time. This gradual decay of the product forma tion velocity over time, however, has to be considered, which is realized in our approach by integrating the velocity over the incubation time, resulting in the term η IC 50
. k inact . t in the denominator of the central relation (23) . A characterization solely based on reaction velocities is questionable.
To access the drugdrug interaction potential of new com pounds, in vitro studies using liver microsomes, hepatocytes, or recombinant CYPs are being applied. 2, 7 We applied our approach in the context of drugdrug interaction because experimental data are readily available and because irreversible inactivation is the underlying mechanism of some of the most important drugdrug interactions of greatest magnitude 2 -for example, paroxetine and CYP2D6, 3 clarithromycin and CYP3A, 4 and furanocoumarins and CYP3A. 5 As reported by Yan et al. 22 and Naritomi et al., 21 irreversible CYP inhibition can easily be distinguished from reversible inhibition by comparing the timedependent pattern of IC 50 val ues from CYP inhibition experiments. If a fluorimetric assay is used, data for different time points can easily be obtained by reading the fluorescence intensity for an individual plate at sev eral points in time without stopping the enzymatic reactions. Therefore, estimating IC 50 values over time using microplate assays is a simple and attractive method to detect irreversible inhibitors. 21 Although this approach allowed for the detection of mechanismbased inhibition, the herein proposed application makes extended use of the same data to also derive K I and k inact values, therefore moving from a simple yes/no statement toward a more quantitative assessment of the DDI potential.
Typically, the experimental determination of K I and k inact values required the performance of additional preincubation experiments, 2 whose data are subsequently analyzed by use of the KitzWilson or nonlinear regression method. 24 The pre sented method, however, allows for the direct estimation of K I and k inact from the set of timedependent IC 50 values.
We have analyzed the accuracy and reliability of the predic tions based on recombinant CYPs and the herein proposed approach for various drugs and the cytochrome P450 isoforms 1A2 and 3A4. The estimated K I and k inact values compare well to published data, except for the K I value of ethinylestradiol and raloxifene. This might be due to limitations of the fluorimetric assay, such as interference from fluorescent inhibitors. In addition, several CYP isoforms may contribute to the formation of the ulti mate CYP inhibitor. Because the substrates for fluorescent assays are not CYP selective and necessitate the use of recombinant singleenzyme systems, the inhibitory effect of metabolites gener ated by one CYP on other CYPs cannot be tested. 25, 26 However, despite these problems, timedependent fluorimetric assays are used to study compounds with respect to potency of MBIs.
2729
To evaluate the robustness of our approach to experimental variability, we estimated K I and k inact based on different sampling protocols and repeated experiments for verapamil, furafylline, and ethinylestradiol. The good agreement between our model predictions and the experimental IC 50 values shows that the derived relation is capable of predicting timedependent IC 50 values as different, as shown in Figure 5 .
Estimated K I values varied roughly 2fold, whereas k inact values varied to a larger extent (almost 10fold). As expected, this shows the variability of the underlying biological system, which can also be observed in the reported literature values (e.g., furafylline or erythromycin). Given the inherent variabil ity of the literature values, results are in good agreement with published experimental data (i.e., less than 2.5fold deviation from a literature value).
In summary, the presented approach allows for the direct use of timedependent IC 50 data to estimate the kinetic parameters of inactivation (K I , k inact ). Streamlining the process of evaluat ing mechanismbased enzyme inactivation is of great interest and importance to the drug discovery process. The design of new experimental approaches aiming at mechanismbased inhibitors necessitates the knowledge of the relation between timedependent IC 50 values and the underlying parameters of inactivation K I and k inact (see, e.g., Berry and Zhao 30 ). The herein derived central relation provides the required theoretical foundation. We would like to point out that the presented approach will also be very useful in cases where mechanism based inhibition is a desired property (e.g., targeting enzymes in cancer therapy). (23) and comparison with the relation derived in Maurer et al. 23 Left: Using equation (19) , product formulation over 30 min was simulated with increasing concentrations of a mechanismbased inhibitor from 0 µM (top) to 9 µM (bottom). The parameters V max , K m , K I , S, and k inact were set to 100 µM/min, 2.5 µM, 2.5 µM, 5 µM, and 0.5 min -1 , respectively (as in Maurer et al. 23 ). Right: Comparison of theoretical IC 50 values (solid line) with predictions resulting from the herein proposed relation equation (23) For each compound, a potential range of data for K I (here 030, or 090) and k inact (here 01) has been depicted. Values with bars pointing downwards refer to literature data, whereas bars pointing upwards refer to own determinations. Estimates by using the here proposed method are based on experimental data from CYP inhibition assays using fluorescent substrates described earlier. Literature data are based on human liver microsomes. Units: K I in µM and k inact in min -1 .
